SSRG International Journal of Polymer and Textile Engineering
ISSN: 2394 – 2592 / https://doi.org/10.14445/23942592/IJPTE-V11I2P101

Volume 11 Issue 1, 1-12, May-Aug 2024

Review Article

Innovations in Polymer Science for Enhanced Pharmaceutical Delivery Systems

Kehinde Esther Ayodeji

Department of Chemistry, Pittsburg State University, Kansas, United States of America.

Corresponding Author : kayodeji@gus.pisttate.edu

Received: 15 June 2024 Revised: 22 July 2024 Accepted: 08 August 2024 Published: 29 August 2024

Abstract *- This study reviews innovations in polymer science for enhanced pharmaceutical delivery systems. The study focuses on significant advancements in the synthesis and design of polymers, examining their potential to improve the effectiveness of therapeutic treatments. It also discusses future possibilities and obstacles through a thorough analysis of existing research. This analysis has demonstrated that notable advancements in the process of creating and structuring polymers have resulted in the creation of intelligent and reactive polymers. In addition, the incorporation of nanotechnology into polymeric carriers has enhanced drug solubility, enabled targeted distribution, and facilitated controlled release mechanisms. Furthermore, both passive and aggressive targeting techniques demonstrate improved therapeutic effectiveness. Moreover, sophisticated polymers show promise in surmounting physiological obstacles, including the blood-brain barrier and mucus layers. Controlled release technologies, such as pH-responsive, temperature-sensitive, and biodegradable systems, enhance medication administration. Additionally, mixed treatments and theragnostic based on polymers in new sectors show potential for personalized medicine. Therefore, it is advisable that future research should prioritize the development of multifunctional polymer systems that integrate therapeutic and diagnostic capabilities. Furthermore, it is imperative to do further research on how to overcome biological obstacles and enhance the long-term durability of polymer-drug formulations in order to advance the area.*

Keywords *- Advancement, Drug Release, Nanotechnology, Medicine.*

1. Introduction

Polymers have had a substantial impact on the development of medicine, being used from ancient times by various civilizations [1]. As a result, pharmaceutical drug delivery technologies have transformed by improving the effectiveness of therapy and patient satisfaction owing to the account that they address healthcare challenges around major medical domains [2].

Treatment of patients has been made more effective by the latest advances in chemical research, such as extended-release formulations, surface modifications of drug careers and delivery methods based on biotechnology [3]. Nevertheless, despite these noteworthy advancements, a number of pressing issues with medication delivery still exist, indicating glaring research gaps that require attention.

The main issue with conventional drug delivery techniques is their inability to target specific certain body regions, enhance bioavailability, and adequately manage drug release systems. This frequently leads to worsening side effects, inadequate patient compliance, and less-than-ideal treatment results. Based on the qualities they possess, such as their adaptable and adjustable features, polymers have become a viable answer to these problems. Molecular engineering of polymers has created new opportunities for the development of intelligent, adaptable, and extremely effective drug delivery systems.

The need to address enduring issues such as low drug solubility, quick clearance, and off-target effects has led to a rise in research on polymer-based drug delivery systems in recent years [4]. Although these systems can cross biological barriers, react to physiological stimuli, and release therapeutic substances under controlled conditions [5], significant research gaps remain, such as 1) synthesizing stimuli-responsive polymers which respond faster and with greater sensitivity to biological cues [6], 2) enhancing highly specific targeting precision, especially in heterogeneous diseases like cancer [7], 3) improving long-term safety of novel synthetic polymers in the body [8], 4) advancing combinations of polymer conjugates and hybrid materials for simultaneous drug delivery and diagnostics [4], and 5) bridging the translational gap between laboratory innovations and clinical practice. Issues of scalability, reproducibility, and regulatory approval present major hurdles in bringing novel delivery systems to market [9].

The evidence of continued innovation in polymer science for drug delivery is emphasized in the research gaps. Hence, this industry needs to adopt a diversified approach in order to develop forward-thinking medication delivery systems that can get beyond current obstacles and significantly improve patient outcomes, which involve merging developments in polymeric chemistry, nanotechnology, and biomedicine.

The goal of this review paper is to present a thorough summary of the most recent advancements in polymer science for improved drug delivery systems. In order to demonstrate the groundbreaking possibilities of polymer chemistry in furthering pharmaceutical research and enhancing patient care, this study will look at recent advances in polymer synthesis, design approaches for getting past biological barriers and developing applications in targeted and controlled drug delivery. In addition, it will evaluate the difficulties of the present and suggest ways forward to fill in the known research gaps, opening the door to safer, more unique, and more efficient drug delivery systems.

2. Breakthroughs in Polymer Synthesis and Design

Polymer science discoveries changed drug delivery by giving exact control over substance properties and drug release patterns. With many uses in the healthcare and pharmaceutical industries, this has had an important effect on patient care and medical procedures. [2, 10]. The evolution of polymeric drug delivery systems highlights the adaptability and potential of these materials, with innovations ranging from traditional methods to cutting-edge technologies.

Drug delivery systems are based on conventional polymer synthesis techniques like chain-growth and step-growth polymerization. Hence, typical plastics consisting of polystyrene and polyethene are created via chain-growth polymerization, which uses unbalanced monomers like vinylic compounds [16]. As a result, polymers having a progressive rise in molecular weight, such as polyesters and polyamides, are produced using step-growth polymerization. At the same time, block copolymer manufacturing is made possible by sophisticated methods such as live polymerization, which also provide more control over molecular weight [17].

However, new technologies have opened up a lot of options for drug delivery using polymers. Complex structures can now be produced quickly and effectively by combining click chemistry and controlled polymerization techniques like RAFT and ATRP [18, 19]. Also, the creation of various macromolecular structures with improved functionality has proven to be very beneficial when this combination is used [20].

Table 1. Polymer technologies in drug delivery can be broadly categorized into traditional and emerging approaches

Category	Polymer Technology	Usage in Drug Delivery
Traditional	Chain-growth polymerization	Production of common polymers like polystyrene and polyethylene for basic drug carriers
	Step-growth polymerization	Creation of polyesters and polyamides for controlled-release formulations
	Living polymerization	Precise control of molecular weight and block copolymer production for tailored drug delivery systems
	Electrospinning	Production of high surface area-to-volume ratio nanofibers for drug-loaded patches or implants
Emerging	Click chemistry with RAFT/ATRP.	Rapid creation of complex polymer structures for advanced drug delivery vehicles
	Nanocomposites	Enhanced mechanical, thermal, and electrical properties for smart drug delivery systems
	3D printing	Customized geometries and internal structures for personalized drug delivery devices
	4D printing	Dynamic, stimuli-responsive structures for targeted and controlled drug release
	Shape Memory Polymers SMP	Temperature-responsive drug release systems
	Multi-material 3D printing	Complex, multifunctional drug delivery devices
	Polymer-textile hybrids	Wearable drug delivery systems
	Biodegradable polymers (e.g., PLA)	Environmentally friendly and biocompatible drug carriers
	Polymers having continuous fiber reinforcement.	Harder, longer-lasting embedded drug delivery systems.
	Conductive hydrogels	Flexible strain sensors for responsive drug delivery systems
	PEDOT: PSS hydrogels	Electrically controlled drug delivery systems
	Origami-inspired 4D printing	Transformable structures for adaptive drug delivery in the body
	Keratin-based materials	Moisture-sensitive, biocompatible drug delivery systems

Source: (Franco, 2024)

Furthermore, the production of polymers has been transformed by nanotechnology, especially in the areas of 3D printing and electrospinning. These methods have made it possible to produce polymer nanofibers with high surface area-to-volume ratios, which are perfect for tissue engineering and filtration applications [21]. Improved mechanical, thermal, and electrical properties of nanocomposites have been achieved through the integration of nanoparticles into polymers [22]. Findings by Franco [11], Yan et al. [12], Khalid et al. [13], Jamal et al. [14] and [15] emphasized other notable technologies which have opened up options for drug delivery using polymers:

- Shape memory polymers (SMPs) and 4D printing technology are two recent developments that provide previously unheard-of control over drug release processes. These materials may allow tailored medication release in response to variations in body temperature since they have the ability to change over time in reaction to external stimuli.

  The ability to produce complex things with many polymer kinds using multi-material 3D printing has made it possible to build drug delivery devices that are more functional and detailed. Wearable medication delivery systems are now possible because of the direct 3D printing of polymers onto textiles to create hybrid polymer-textile structures.

- Biodegradable polymers, including polylactic acid (PLA), are being developed in response to the increasing demand for biocompatible and ecologically acceptable materials in medication delivery. Researchers have also started to improve the mechanical characteristics of drug delivery systems by adding continuous fibres, like carbon fibre, to polymer filaments.

- Within the field of smart materials, PEDOT: PSS hydrogels and conductive hydrogels hold potential as electrically controlled and responsive drug delivery systems. Origami-inspired researchers have used 4D printing to create intricate, morphable structures that may eventually lead to medication delivery systems that may unfold or reshape inside the body.

- Lastly, a major advancement in bioengineering and smart textiles for medication delivery is the utilization of keratin-based materials with shape memory and moisture-sensitive qualities. These biocompatible materials provide the possibility of developing medication delivery systems that adapt to the body's normal moisture levels.

When taken as a whole, these developments mark a substantial advancement in additive manufacturing for drug delivery applications and polymer science. Innovative materials and fabrication methods are enabling researchers to design more complex, customized, and responsive medication delivery systems that could completely change the way patients are treated.

3. Nanotechnology in Polymeric Drug Carriers

A state-of-the-art method in pharmaceutical research, nanotechnology in polymeric drug carriers offers improved effectiveness, less negative consequences, and targeted administration [23]. According to [23], it can get beyond biological barriers and make it easier to distribute drugs to previously unreachable locations, e.g. liposomes, polymeric nanoparticles, dendrimers, and micelles.

Accordingly, polymeric nanocarriers solve problems, including excessive amounts to be taken, short-term fluctuations in drug-focused attention, low solubility, and drug degradation. It can be programmed to deliver medication at particular times and places as well as to react to outside cues [24]. Also, immunomodulation, infectious illnesses, and cancer have all shown promise for the use of polymers in drug delivery systems, including polymeric nanoparticles [7]. According to [7], drugs' biopharmaceutical and biokinetic behaviour can be altered by these systems, improving their durability and potency while lowering cytotoxicity.

Moreover, polymers are essential for colloidal drug carrier systems and drug delivery devices such as implants for regulated drug delivery [25]. They have benefits, including improved drug release and loading characteristics, blood-brain barrier crossing, and resistance to chemical deterioration. In recognition of their capacity to strengthen drug solubility, facilitate targeted delivery, regulate discharge, and shield pharmaceuticals from deterioration, polymeric nanocarriers such as nanoparticles, micelles, dendrimers, and polymersomes have drawn a lot of interest in the field of drug delivery [24, 26]. These carriers are especially helpful for tailored and prolonged drug administration as well as for improving therapeutic effectiveness; their sizes tend to vary from 10 to 1000 nanometers.

Due to the predicted expansion of consumer demand for medication delivery systems based on nanotechnology, the use of polymeric nanocarriers will likely continue to grow [27]. A typical instance is the utilization of poly(lactic-co-glycolic acid) (PLGA) nanoparticles. A large amount of investigation has been conducted on the prospective application of PLGA nanoparticles in cancer treatment, specifically in regard to the governance of cancer chemotherapy drugs like paclitaxel. In recent studies, these nanoparticles may decrease the adverse impacts of paclitaxel while improving its potency [28].

Also, continuous studies have been done on the application of PLGA nanoparticles in cancer medication delivery systems, with an emphasis on their controlled release, biodegradability, and biocompatibility [29]. With a focus on their ability to address the unfavourable aspects of anticancer

medications, the adaptability of PLGA nanoparticles in the distribution of anticancer treatments has been emphasized [30].

Amphiphilic block copolymers give rise to polymeric micelles, a diverse family of nanocarriers with possible uses in drug administration, including tissue penetrability, less toxicity, and controlled drug release, among its benefits [68]. These characteristics make them especially suitable for long-term release, solubilizing poorly soluble compounds, and shielding encapsulated materials from metabolism and breakdown [65]. Consequently, polymeric micelles have demonstrated the possibility of being used in the treatment of cancer, offering a safe and efficient means of addressing incurable diseases [69]. Notably, paclitaxel's polymeric micelle formulation, Genexol-PM, has shown enhanced efficacy in treating a range of malignancies [66].

Research on smart polymeric nanocarriers is moving quickly forward and has the potential to significantly change drug delivery in complex diseases like cancer and neurodegenerative disorders. These nanocarriers, in particular, are responsive to stimuli like pH, temperature, and specific enzymes [34]. These nanocarriers, such as those made of poly(histidine), have demonstrated potential for the targeted delivery of medications to tumour settings [35]. The inclusion of targeted ligands further enhances the specificity of these carriers, as aptamer-functionalized PLGA nanoparticles have shown in the delivery of docetaxel to prostate cancer cells [36]. Current research focuses mostly on the use of stimuli-responsive polymeric nanocarriers in cancer therapy, especially those that may release their payload in response to an internal or external trigger [37]. These nanocarriers may promote drug dispersion, lessen adverse drug reactions, and improve in vivo drug delivery [34].

From the foregoing, it is evident that the literature has provided ample substantiation of the potential of polymeric drug carriers to transform drug delivery for diseases as complex as cancer and neurological disorders. Polymeric PLGA-based nanoparticles have been shown to have promise in the treatment of neurodegenerative diseases [39, 40], especially in terms of better drug targeting and permeability across the blood-brain barrier. The importance of polymeric nanocarriers in developing nanoreactors for in situ drug administration, as well as in preserving and delivering active chemicals to diseased locations, is further highlighted by [41] and [42]. All of these findings highlight how important polymeric drug carriers can be in improving the way complex diseases are treated.

4. The Use of Polymers for Targeted Drug Delivery

Pharmaceutical research has improved greatly with the use of polymers for targeted drug delivery, which allows for the accurate, effective, and regulated blend of medicinal substances through passive and active targeting mechanisms [63]. According to [72], active targeting involves functionalizing polymeric carriers with particular ligands, while passive targeting, on the other hand, makes use of natural polymer characteristics.

However, the polymer's size, charge, and hydrophobicity/hydrophilicity balance, among other things, have a big impact on how long it takes for polymeric substances to circulate and where they end up in tissues [62]. Also, polymeric nanoparticles can be surface-decorated with tumor-homing ligands to promote their retention and accumulation in the tumour vasculature, which could result in better treatment outcomes. However, drug delivery can benefit greatly from polymeric systems, as summarized in Table 2 above, especially poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which offer stability to labile molecules, regulated release to the intended place, and the capacity to alter surfaces for targeted delivery while shielding pharmaceuticals from deterioration and premature release [8].

In order to overcome some of the limitations related to PLGA nanoparticles, hybrid PLGA nanoparticles, which integrate several functions, have been produced [70]. With an emphasis on PLGA in particular, the stability and promise of polymeric nanoparticles in anti-neoplastic therapeutic research have been emphasized [67]. Because of their biodegradability, biocompatibility, and capacity to shield medications from deterioration, PLGA-based nanoparticles have been effectively employed in a number of biological applications, such as cancer, inflammation, and vaccination [31]. In the same vein, PEGylated polymers have a lot to offer in terms of medication delivery, such as customization for particular uses, including injectable polymer-drug conjugates and implants [32]. These technologies are very useful for drug delivery because it has been demonstrated that they lengthen the duration of drug circulation and decrease immunogenicity [25]. Nonetheless, studies are still being conducted to create substitute polymer-drug conjugates that provide improved degradability and stability [33].

Similarly, methacrylic acid, a pH-responsive polymer, has been found to be an essential tool in cancer treatment, enabling targeted drug delivery to tumour areas [34]. These systems belong to a larger class of stimuli-responsive polymers, which are able to alter their microstructure in reaction to various environmental stimuli, such as pH variations [64]. Drug delivery relies heavily on this capacity to react to certain circumstances since it enables the controlled and targeted release of therapeutic substances [4]. The fact that these systems are used in polymeric nano vehicles for anticancer medications, which may be made to release medications in response to particular triggers like an acidic pH in tumour settings, serves as additional evidence of their potential [38].

Table 2. Types of polymer for targeted drug delivery

Polymer Type	Key Features	Advantages	Applications	Targeting Mechanism
PLGA (Poly(lactic-co-glycolic acid))	Biodegradable and biocompatible, it protects drugs from degradation and allows surface modification and Hybrid versions are available.	Controlled release, Stability for labile molecules, Targeted delivery and Prevents premature release.	Vaccination, Cancer therapy, Inflammation treatment and Anti-neoplastic drug research	Passive targeting and Active targeting (with surface modification)
PEGylated polymers	It can be tailored for specific applications, Increases drug circulation time, and is Water-soluble.	Reduced immunogenicity, Improved pharmacokinetics, Reduced toxicity, Enhanced stability	Injectable polymer-drug conjugates, Implants, Targeted drug release	Passive targeting and Active targeting (with ligand attachment)
pH-responsive poly(methacrylic acid)	Changes in microstructure in response to pH allow for precise drug delivery to tumor sites, which is part of stimuli-responsive polymers.	Controlled and targeted release, responded to the acidic tumor environment and triggered release.	Cancer therapy, Polymeric nano vehicles for anticancer drugs	Active targeting (pH-responsive)
General polymeric systems	Size, charge, and hydrophobicity/hydrophilicity balance affect distribution, Can be decorated with tumor-homing ligands, High loading efficiencies	improved retention in the cancer vasculature, improved effectiveness of therapy, drug shielding able to reply to outer factors	improved retention in the cancer vasculature, improved effectiveness of therapy, drug shielding able to reply to outer factors	Passive targeting (size and charge) and Active targeting (ligand decoration)

Consequently, recent years have seen substantial breakthroughs in polymeric systems for targeted drug administration, with an emphasis on improving therapeutic efficacy and safety, especially in the areas of cardiovascular, neurodegenerative, and cancer treatments. The promise of polymeric nanoparticles and polymer-drug conjugates in targeted cancer therapy is further highlighted by [43], [44], and [45] respectfully. Taken together, these studies demonstrate the ongoing development and promise of polymeric systems for targeted drug delivery.

5. Overcoming Physiological Barriers with Advanced Polymers

One of the primary objectives of pharmaceutical development is the eradication of physiological barriers. [46] contends that although these barriers—which include cellular, tissue, enzymatic, and chemical barriers—are vital to sheltering the body from perhaps hazardous substances, they also create problems for the delivery of drugs. It further influences drug delivery by affecting bioavailability, drug stability, targeting, and dosage requirements, which can reduce the amount of drug that reaches systemic circulation intact, degrade drugs before absorption, prevent drugs from reaching specific tissues or organs, and necessitate higher doses to overcome their effects, potentially increasing side effects. Consequently, researchers are now working on the development of advanced polymers to address the challenges posed by physiological barriers in drug administration [47].

For instance, polymers, like PEG, are used to prolong the time that drugs remain in circulation and improve their effectiveness. It also has a vital function in the regulated distribution of medicinal substances [4]. Also, biodegradable polymers have shown the capacity to enhance retention duration and bioavailability in ocular medication administration [48].

As a result, researchers like [49], [43], [44], and [45] are now investigating localized polymer depot delivery systems for the treatment of cancer, with the aim of enhancing the ability of drugs to penetrate and be transported throughout the body. These studies together demonstrate the capability of improved polymers to overcome physiological obstacles in medication administration.

The blood-brain barrier (BBB) and mucus layers, in particular in the central nervous system and mucosal tissues, substantially restrict the delivery of drugs. To get around these difficulties, researchers are now researching polymer-based nanocarriers. Resultantly, polysorbate 80-coated nanoparticles have shown potential in transporting medications to the brain by imitating low-density lipoproteins [50, 51].

Moreover, studies have shown that mucus-penetrating nanoparticles composed of densely PEGylated polymers exhibit enhanced diffusion through mucus layers compared to traditional particles. This advancement has led to improved medication delivery for illnesses such as cystic fibrosis and inflammatory bowel disease [52, 53]. Hence, the progress in nanocarrier technology has significant promise for surmounting the blood-brain barrier (BBB) and mucus barriers in medication delivery.

Up to this point, research has focused on creating polymers to deliver medicines verbally, with an emphasis on cancer therapy. The aim of pH-responsive polymers, such as Eudragit®, is to release drugs into the more alkaline environment of the intestine whilst preserving them from the acidic conditions of the stomach [54]. Some polymers, like the mucoadhesive polymer chitosan, have the capacity to boost the absorption of drugs in the intestines. Furthermore, the utilization of polymeric nanocarriers carrying P-glycoprotein inhibitors offers the potential to reduce cancer cells' multidrug resistance. Additionally, physiological constraints have been overcome with customized drug release at certain locations made possible using stimuli-responsive polymers, such as thermosensitive polymers [54].

As the comprehension of biological obstacles progresses, the complexity of polymer-based solutions also increases. Improved techniques to penetrate beyond physiological barriers arise from the combination of many properties, such as stimuli-responsiveness, targeting ligands, and stealth—into a single polymeric organization. Therefore, advances in advanced polymer design are serving to enhance patient outcomes across multiple therapeutic areas through the creation of superior drug delivery systems.

6. Mixture Therapies and Theranostics Based on Polymers

Polymer-based combination therapies and theranostics, which have boosted therapeutic efficacy and diagnostic opportunities, have made significant improvements in the area of medicine.

These technologies, especially in the domain of cancer research, have the capacity to transform patient care by offering continuous monitoring of treatment response and accurate administration of medication [55]. Hence, polymer-based materials provide a high degree of adaptability, allowing them to remain in the bloodstream for prolonged durations and concentrate in particular regions.

This characteristic renders them well-suited for targeted medication administration and imaging purposes [56]. The research on developing multifunctional polymer-based materials for image-guided cancer treatment shows great promise and is now expanding [57].

From the preceding, dendrimer-based systems have emerged as a prominent class of polymer-based materials for theranostic applications. These highly branched, tree-like structures, as in Figure 1, offer unique advantages due to their multifunctional nature and ability to carry both therapeutic and diagnostic agents.



Fig. 1 Schematic description of thernostic dendrimer
Source: Serge et al. (2018)

Dendrimers with distinct generations and compositions can be modified absolutely by theranostic applications, as indicated in Table 3. PAMAM dendrimers, for such as have been enriched with lots of therapeutic (doxorubicin, methotrexate, siRNA) and imaging (fluorescent dyes, radioisotopes, magnetic nanoparticles) agents for use in the treatment and diagnosis of cancer.

Multiple functionalities might be implemented in dendrimer-based systems, confirming their flexibility. As a demonstration of the prospect for multimodal cancer treatment, Zhong Yuan Chen et al. reported on a magnetic nano-octahedron system enriched with aptamer and dendrimers that might deliver magnetic hyperthermia and chemotherapy constantly.

For theranostic applications, polymer-based compounds, including dendrimers, provide a number of benefits. These materials can increase the effectiveness of their therapy by achieving focused accumulation in particular tissues and an extended circulation time. In addition, they have the capacity to transport several therapeutic substances, which permits combination therapy methodologies.

Real-time monitoring of treatment response is made possible by the imaging capabilities integrated into these materials, which offer important insights into the efficacy of the therapy. Additionally, stimuli-responsive qualities, including pH-responsive systems, can be built into polymer-based materials to allow for targeted and controlled medication release.

Table 3. Summary of dendrimer-based theranostic systems

Dendrimer Type	Generation	Therapeutic Agent	Diagnostic Agent	Therapeutic Role	Diagnostic Role	Target/Application
Cationic carbosilane	G2	siRNA	Isothiocyanate of Fluorescein (FI)	Gene silencing	Fluorescence imaging	HIV-infected human primary astrocytes
PEGylated	G2.5	Doxorubicin (DOX)	SPIO nanoparticles	Cancer therapy	MRI	Cancer therapy and imaging
PAMAM	G3	Methotrexate (MTX)	Isothiocyanate of Fluorescein (FI)	Targeting and killing FR-expressing tumor cells	Fluorescence imaging	FR-expressing tumor cells
PEGylated PAMAM	G3.5	Doxorubicin (DOX)	SPIO nanoparticles	Cancer therapy	MRI	Cancer therapy and imaging
mPEG-PAMAM	G3.5	Taxol	SPIO nanoparticles	Cancer therapy	MRI and fluorescence imaging	Cancer therapy and imaging
PAMAM glycidol hydroxyl-terminated	G4	-	Bi	-	CT imaging	Animal models
PPI with LHRH peptide	G4	Pcs	Pcs	Cancer therapy	Fluorescence imaging	Human ovarian carcinoma
PEG-PAMAM-FA	G4	5-FU	99mTc	Cancer treatment	γ-Camera imaging	MCF-7 cell lines
PAMAM	G5	Methotrexate (MTX)	Fluorescein isothiocyanate (FI)	Targeting FR-expressing cells	Fluorescence imaging	KB cell line
PAMAM	G5	Taxol	Cy5	Cancer therapy	Flow cytometry	Cancer cells
PPI	G5	Naphthalocyanine	Naphthalocyanine or SiNc	Cancer therapy	Fluorescence imaging	Resistant ovarian cancer
PAMAM	G5	α-Tocopheryl succinate	Fluorescein isothiocyanate (FI)	Cancer therapy	CT imaging	Hepatocellular carcinoma
PAMAM	G5	hNIS gene	123I	Gene therapy	PET imaging	Liver cancer
PAMAM with RGD	G5	Doxorubicin (DOX)	Fluorescein isothiocyanate (FI)	Cancer therapy	Fluorescence imaging	Glioblastoma cancer cells
PAMAM-PLL	G6	Poly-L-lysine (PLL)	-	Systemic antiangiogenic activity	-	Angiogenesis inhibition

Source: Hosseini et al., (2023)



Fig. 2 Diagrammatic indicating of a versatile theranostic system based on dendrimers

Source: Warsi et al. (2016)

Finally, polymer-based combination treatments and theranostics, especially those that make use of dendrimer systems, provide enormous opportunities for specialized medical treatments.

These approaches offer the potential for tailored treatments based on real-time patient feedback, potentially improving outcomes across a range of diseases, notably in cancer and chronic disorders. Further developments in the production and use of multifunctional polymer-based materials for image-guided therapies and individualized treatment will be made as this field of study continues to advance [57].

8. Potential for the Future and Today in Polymer-Based Drug Delivery

Drug delivery systems which are based upon polymers have drastically enhanced patient satisfaction overall and the potency of therapies. Meanwhile, there are still unresolved issues, and how satisfactorily they are settled will influence the future of this domain. The present obstacles are as follows:

- Biocompatibility and decomposition: When a variety of polymers shows bio-compatibility, the ongoing impacts on various modern synthetic polymers remain uncertain. It is vital to make sure that an item totally melts down without producing any dangerous byproducts.
- A major obstacle is achieving scalability while creating the move from small-scale production in the lab to huge-scale manufacturing in an industrial setting while preserving consistent quality.
- Regulatory Problems: Complicated polymer-based systems, mainly those with many parts (medicines and imaging agents), have to undergo strict regulatory scrutiny, ending in a lengthy licensing technique.
- Precise Delivery: Despite progress, attaining very accurate targeting without unintended consequences remains difficult, especially in complex illnesses such as cancer.
- The commercial appeal of polymer-drug formulations is reliant on this ability to sustain their integrity under different situations of storage, resulting in long-term stability and shelf-life vital parts.
- Breaking Biological Barriers: It is also challenging to successfully pass biological barriers, like cell membranes and the blood-brain barrier while preserving their integrity.

8.1. Potential for the Future

- Personalized Medicine: Progress in polymer chemistry may facilitate the creation of adaptive drug delivery systems that may adjust to the specific features of individual patients and their medical conditions.
- By increasing the precision and effectiveness, drug delivery systems could be made better by merging nanotechnology and polymer science.
- More aimed and consistent drug release could be made feasible by the development of polymers that act with a

range of stimuli, such as changes in pH, temperature, or the presence of enzymes.

- Polymeric carriers have the potential to address the obstacles encountered in gene therapy and siRNA distribution, which might possibly transform the treatment of genetic diseases and cancer.
- The use of 3D printing technology could speed up the production of customized polymer-based systems for drug delivery, as requested.
- Artificial Intelligence and Machine Learning: These technologies may boost polymer design and foresee in vivo performance, which might speed up the development process.
- Mixture of Immunotherapies: Polymer-based systems offer an opportunity to improve the favourable effects of immunotherapies by providing immunomodulators and immune response control.

Newer polymer designs might be the key to tackling treatment resistance in conditions such as cancer and bacterial infections.

Research advances are expected to lead to a generation of polymer-based drug delivery systems which are safer, more individualized, and more powerful. This might dramatically change how therapeutic treatments for different conditions are carried out.

9. Conclusion

The significant improvement in polymer science for drug delivery systems is highlighted in this detailed research, which also reveals how these advances have the potential to revolutionize the effectiveness of treatment and patient outcomes. With new technologies like shape memory polymers, biodegradable materials, and 3D and 4D printing opening up novel opportunities for delivering drugs, science has seen enormous strides in polymer synthesis and design.

With nanoparticles, micelles, and dendrimers exhibiting ability in targeted treatment, controlled release, and overcoming physiological difficulties, nanotechnology has been essential to enhancing polymeric drug carriers. The precision and efficacy of drug delivery systems were greatly enhanced by the development of smart, stimuli-responsive polymers, specifically for challenging therapeutic areas like cancer treatment. A crucial step towards personalized medicine was made with the integration of polymers in combination therapies and theragnostic, permitting real-time monitoring of treatment response and customized techniques for therapy. Dendrimer-based equipment displayed a phenomenal amount of flexibility when merging diagnostic and therapeutic activities. Regardless of these changes, there are still difficulties with biocompatibility, scalability, regulatory approval, and formulations based on polymers' long-term stability. For these modern ways of delivery to be commonly employed in medical settings, it will be important to address these concerns. The field of polymer-based drug delivery offers a lot of possibilities moving forward. New developments will be made as polymer science and modern areas like nanotechnology, 3D printing, and artificial intelligence merge together. These improvements might end up in greater safety, efficacy, and customized methods of treatment for various kinds of illnesses.

Let me conclude by stating that polymer studies continue to expand the boundaries of pharmaceutical delivery, offering answers to ongoing issues with drug administration and creating opportunities for new therapies. We might expect improved, reliable medication delivery systems that may entirely change patient care and treatment outcomes as this field study develops.

Acknowledgements

The dynamic efforts and contributions made by Adedeji T. E. are well acknowledged and appreciated.

References

[1] Kehinde Esther, and Ayodeji, “Review of the Impact of Polymers on the Pharmaceutical Industry,” *International Journal of Novel Research and Development*, vol. 9, no. 1, pp. 199-208, 2024. [Publisher Link]

[2] Rahul Bijwar, and Harshal Tare, “Revolutionizing Medicine: Advances in Polymeric Drug Delivery Systems,” *International Journal of Drug Delivery Technology*, vol. 14, no. 1, pp. 572-580, 2024. [CrossRef] [Publisher Link]

[3] Suruchi Yadav, “Advancements in Pharmaceutical Formulation Development and Drug Delivery Systems,” *The Pharma Innovation International Journal*, vol. 8, no. 1, pp. 870-874, 2019. [CrossRef] [Publisher Link]

[4] William B. Liechty et al., “Polymers for Drug Delivery Systems,” *Annual Review of Chemical and Biomolecular Engineering*, vol. 1, pp. 149-173, 2010. [CrossRef] [Google Scholar] [Publisher Link]

[5] Priyanka Ray, “Polymer Based Drug Delivery Systems-Benchtop to Bedside Transition,” *Journal of Drugs Addiction and Therapeutics*, vol. 2, no. 2, pp. 1-3, 2021. [CrossRef] [Google Scholar] [Publisher Link]

[6] Avinash Kumar Seth et al., “Smart Polymer Systems: A Futuristic Approach to Enhance Therapeutic Efficacy,” *Current Organic Chemistry*, vol. 28, no. 15, pp. 1164-1178, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[7] Laura Jaimes-Aguirre et al., “Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status,” *Current Pharmaceutical Design*, vol. 22, no. 19, pp. 2886-2903, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[8] Mamta Saiyad, and Nimish Shah, “Nanopolymers in Drug Delivery System,” *Materialstoday: Proceedings*, vol. 67, no. 1, pp. 25-30, 2022. [CrossRef] [Google Scholar] [Publisher Link]

[9] Caizhi Liao, Shadow Xiao, and Xia Wang, "Bench-to-Bedside: Translational Development Landscape of Biotechnology in Healthcare," *Health Sciences Review*, vol. 7, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[10] Zoilo González, Ana Ferrández-Montero, and Juan Domínguez-Robles, "Recent Advances in Polymers as Matrices for Drug Delivery Applications," *Pharmaceuticals*, vol. 16, no. 12, pp. 1-4, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[11] Edgar Adrian Franco Urquiza, "Advances in Additive Manufacturing of Polymer-Fused Deposition Modeling on Textiles: From 3D Printing to Innovative 4D Printing - A Review," *Polymers*, vol. 16, no. 5, pp. 1-23, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[12] Shiyu Yan et al., "Shape Memory Polymer Composites: 4D Printing, Smart Structures, and Applications," *Research A Science Partner Journal*, vol. 7, pp. 1-25, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[13] Muhammad Yasir Khalid et al., "Review: 4D Printing of Shape Memory Polymer Composites: A Review on Fabrication Techniques, Applications, and Future Perspectives," *Journal of Manufacturing Processes*, vol. 81, pp. 759-797, 2022. [CrossRef] [Google Scholar] [Publisher Link]

[14] Muhammad Azfar Jamal et al., "Additive Manufacturing of Continuous Fiber-Reinforced Polymer Composites via Fused Deposition Modelling: A Comprehensive Review," *Polymers*, vol. 16, no. 12, pp. 1-33, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[15] Abhijeet Hiwrale et al., "Nanofibers: A Current Era in Drug Delivery System," *Heliyon*, vol. 9, no. 9, pp. 1-20, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[16] Nigel Mills, Mike Jenkins, and Stephen Kukureka, "Chapter 2-Molecular Structures and Polymer Manufacture, *Plastics (Fourth Edition), Microstructure and Engineering Applications*, 2020. [CrossRef] [Google Scholar] [Publisher Link]

[17] Maria Nerantzaki, Capucine Loth, and Jean-François Lutz, "Chemical Conjugation of Nucleic Acid Aptamers and Synthetic Polymers," *Polymer Chemistry*, vol. 12, no. 24, pp. 3498-3509, 2021. [CrossRef] [Google Scholar] [Publisher Link]

[18] David Fournier, Richard Hoogenboom, and Ulrich S. Schubert, "Clicking Polymers: A Straightforward Approach to Novel Macromolecular Architectures," *Chemical Society Reviews*, vol. 36, pp. 1369-1380, 2007. [CrossRef] [Google Scholar] [Publisher Link]

[19] Rong Fu, and Guo-Dong Fu, "Polymeric Nanomaterials from Combined Click Chemistry and Controlled Radical Polymerization," *Polymer Chemistry*, vol. 2, pp. 465-475, 2011. [CrossRef] [Google Scholar] [Publisher Link]

[20] Mehmet Arslan, and M. Atilla Tasdelen, "Click Chemistry in Macromolecular Design: Complex Architectures from Functional Polymers," *Chemistry Africa*, vol. 2, pp. 195-214, 2019. [CrossRef] [Google Scholar] [Publisher Link]

[21] Allison M. Pekkanen et al., "3D Printing Polymers with Supramolecular Functionality for Biological Applications," *Biomacromolecules*, vol. 18, no. 9, pp. 2669-2687, 2017. [CrossRef] [Google Scholar] [Publisher Link]

[22] Tatiya Siripongpreda et al., "Emerging 3D Printing Based on Polymers and Nanomaterial Additives: Enhancement of Properties and Potential Applications," *European Polymer Journal*, vol. 184, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[23] Satyendra Kumar, and Purshotam, "Pharmaceutical Nanotechnology: Applications in Drug Delivery," *The Pharma Innovation International Journal*, vol. 8, no. 4, pp. 1315-1319, 2019. [CrossRef] [Publisher Link]

[24] Payam Abasian et al., "Polymeric Nanocarriers in Targeted Drug Delivery Systems: A Review," *Polymers for Advanced Technologies*, vol. 31, no. 12, pp. 2939-2954, 2020. [CrossRef] [Google Scholar] [Publisher Link]

[25] Apurva Srivastava et al., "Polymers in Drug Delivery," *Journal of Biosciences and Medicines*, vol. 4, no. 1, pp. 69-84, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[26] Natarajan Jawahar, and S. Meyyanathan, "Polymeric Nanoparticles for Drug Delivery and Targeting: A Comprehensive Review," *International Journal of Health and Allied Sciences*, vol. 1, no. 4, 2012. [Google Scholar] [Publisher Link]

[27] Alejandro Sosnik, Angel M. Carcaboso, and Diego A. Chiappetta, "Polymeric Nanocarriers: New Endeavors for The Optimization of The Technological Aspects of Drugs," *Recent Patents on Biomedical Engineering (Discontinued)*, vol. 1, no. 1, pp. 43-59, 2008 [CrossRef] [Google Scholar] [Publisher Link]

[28] S. S. Feng, "Nanomedicine: Nanoparticles of Biodegradable Polymers for Cancer Diagnosis and Treatment," *Cosmos*, vol. 4, no. 2, pp. 185-201, 2008. [CrossRef] [Google Scholar] [Publisher Link]

[29] Tabatabaei Mirakabad et al., "PLGA-Based Nanoparticles as Cancer Drug Delivery Systems," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 2, pp. 517-535, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[30] Iliyas Khan et al., "PLGA Nanoparticles and Their Versatile Role in Anticancer Drug Delivery," *Critical Reviews in Therapeutic Drug Carrier Systems*, vol. 33, no. 2, pp. 159-193, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[31] Fabienne Danhier et al., "PLGA-Based Nanoparticles: An Overview of Biomedical Applications," *Journal of controlled release*, vol. 161, no. 2, pp. 505-522, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[32] Maisie J. Joralemon, Samantha McRae, and Todd Emrick, "Pegylated Polymers for Medicine: from Conjugation to Self-Assembled Systems," *Chemical Communications*, vol. 46, no. 9, pp. 1377-1393, 2010. [CrossRef] [Google Scholar] [Publisher Link]

[33] Emma M. Pelegri-O'Day, En-Wei Lin, and Heather D. Maynard, "Therapeutic Protein-Polymer Conjugates: Advancing Beyond PEGylation," *Journal of the American Chemical Society*, vol. 136, no. 41, pp. 14323-14332, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[34] Sankha Bhattacharya, Bhuphendra G. Prajapati, and Sudarshan Singh, "A Critical Review on The Dissemination of Ph and Stimuli-Responsive Polymeric Nanoparticular Systems to Improve Drug Delivery in Cancer Therapy," *Critical Reviews in Oncology/Hematology*, vol. 185, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[35] Emanuel Fleige, Mohiuddin A. Quadir, and Rainer Haag, "Stimuli-Responsive Polymeric Nanocarriers for the Controlled Transport of Active Compounds: Concepts and Applications," *Advanced Drug Delivery Reviews*, vol. 64, no. 9, pp. 866-884, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[36] Mosa Alsehli, "Polymeric Nanocarriers as Stimuli-Responsive Systems for Targeted Tumor (Cancer) Therapy: Recent Advances in Drug Delivery," *Saudi Pharmaceutical Journal: SPJ*, vol. 28, no. 3, pp. 255-265, 2020. [CrossRef] [Google Scholar] [Publisher Link]

[37] Ali Alsuraifi et al., "Stimuli Responsive Polymeric Systems for Cancer Therapy," *Pharmaceutics*, vol. 10, no. 3, pp. 1-17, 2018. [CrossRef] [Google Scholar] [Publisher Link]

[38] Kyung T. Oh et al., "Polymeric Nanovehicles for Anticancer Drugs with Triggering Release Mechanisms. *Journal of Materials Chemistry*, vol. 17, no. 38, pp. 3987-4001, 2007. [CrossRef] [Google Scholar] [Publisher Link]

[39] Miguel Pinto et al., "Brain Drug Delivery and Neurodegenerative Diseases: Polymeric Plga-Based Nanoparticles as A Forefront Platform," *Ageing Research Reviews*, vol. 79, 2022. [CrossRef] [Google Scholar] [Publisher Link]

[40] Pratik Chakraborty et al., "Polymeric Nanotherapeutics: An Emerging Therapeutic Approach for the Management of Neurodegenerative Disorders," *Journal of Drug Delivery Science and Technology*, vol. 91, no. 3, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[41] Ozana Onaca-Fischer et al., "Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications," *Current Pharmaceutical Design*, vol. 18, no. 18, pp. 2622-2643, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[42] Brittany L. Banik, Pouria Fattahi, and Justin L. Brown, "Polymeric Nanoparticles: The Future of Nanomedicine," *Wiley Interdisciplinary Reviews*, vol. 8, no. 2, pp. 271-299, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[43] Varaporn Buraphacheep Junyaprasert, and Parichart Thummarati, "Innovative Design of Targeted Nanoparticles: Polymer-Drug Conjugates for Enhanced Cancer Therapy," *Pharmaceutics*, vol. 15, no. 9, pp. 1-26, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[44] Ling Ding et al., "Polymer-Based Drug Delivery Systems for Cancer Therapeutics," *Polymers*, vol. 16, no. 6, pp. 1-35, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[45] Farah Al-Sahlawi et al., "Polymer-Based Nanoparticles in Targeted Cancer Therapy: A Review," *Journal of Applied Pharmaceutical Science*, pp. 1-12, 2024. [CrossRef] [Google Scholar] [Publisher Link]

[46] Zhengnan Yang, Dona Foster, and Ali Dhinojwala, "Continuous Production of Polymer Nanoparticles Using a Membrane-Based Flow Cell," *Journal of Colloid and Interface Science*, vol. 501, no. 1, pp. 150-155, 2017. [CrossRef] [Google Scholar] [Publisher Link]

[47] Oliver S. Thomas, and Wilfried Weber, "Overcoming Physiological Barriers to Nanoparticle Delivery-Are We There Yet?," *Frontiers in Bioengineering and Biotechnology*, vol. 7, pp. 1-21, 2019. [CrossRef] [Google Scholar] [Publisher Link]

[48] Courtney Lynch et al., "Advances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery," *Polymers*, vol. 11, no. 8, pp. 1-24, 2019. [CrossRef] [Google Scholar] [Publisher Link]

[49] Jesse B. Wolinsky, Yolonda L. Colson, and Mark W. Grinstaff, "Local Drug Delivery Strategies for Cancer Treatment: Gels, Nanoparticles, Polymeric Films, Rods, and Wafers," *Journal of Controlled Release*, vol. 159, no. 1, pp. 14-26, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[50] Fröhlich, Eleonore, and Roblegg, Eva, "Mucus as Barrier for Drug Delivery by Nanoparticles," *Journal of Nanoscience and Nanotechnology*, vol. 14, no. 1, pp. 126-136, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[51] Weisen Zhang et al., "Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges," *Advanced Science*, vol. 8, no. 10, 2021. [CrossRef] [Google Scholar] [Publisher Link]

[52] Samuel K. Lai, Ying-Ying Wang, and Justin Hanes, "Mucus-Penetrating Nanoparticles for Drug and Gene Delivery to Mucosal Tissues," *Advanced drug Delivery Reviews*, vol. 61, no. 2, pp. 158-171, 2009. [CrossRef] [Google Scholar] [Publisher Link]

[53] S. Dünnhaupt et al., "Nano-Carrier Systems: Strategies to Overcome the Mucus Gel Barrier," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 96, pp. 447-453, 2015. [CrossRef] [Google Scholar] [Publisher Link]

[54] Vijayakameswara Rao Neralla et al., "Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy," *Frontiers in Bioengineering and Biotechnology*, vol. 6, pp. 1-15, 2018. [CrossRef] [Google Scholar] [Publisher Link]

[55] Brian T. Luk, and Liangfang Zhang, "Current Advances in Polymer-Based Nanotheranostics for Cancer Treatment and Diagnosis," *ACS Applied Materials & Interfaces*, vol. 6, no. 24, pp. 21859-21873, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[56] Ortensia Ilaria Parisi et al., "Engineered Polymer-Based Nanomaterials for Diagnostic, Therapeutic and Theranostic Applications," Mini reviews in Medicinal Chemistry, vol. 16, no. 9, 754-761, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[57] Yang Sun, Haitao Ran, Fan Liu, "Polymer-Based Materials and Their Applications in Image-Guided Cancer Therapy," *Current medicinal chemistry*, vol. 29, no. 8, pp. 1352-1368, 2021. [CrossRef] [Google Scholar] [Publisher Link]

[58] Serge Mignani et al., "Recent Therapeutic Applications of the Theranostic Principle with Dendrimers in Oncology," *Science China Material*, vol. 61, pp. 1367-1386, 2018. [CrossRef] [Google Scholar] [Publisher Link]

[59] S.M. Hosseini et al., "Theranostic Polymeric Nanoparticles as A New Approach in Cancer Therapy and Diagnosis: A Review," *Materials Today Chemistry*, vol. 29, pp. 1-16, 2023. [CrossRef] [Google Scholar] [Publisher Link]

[60] Yinan Zhong et al., "Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy," *Biomacromolecules*, vol. 15, no. 6, pp. 1955-1969, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[61] Musarrat Husain Warsi et al., *Drug Delivery Potential of Dendrimeric Formulation*, Dendrimers in Nanomedicine, 1St Ed., pp. 1-21, 2021. [Google Scholar] [Publisher Link]

[62] Joseph Jagur-Grodzinski, "Polymers for Targeted And/Or Sustained Drug Delivery," *Polymers for Advanced Technologies*, vol. 20, no. 7, pp. 595-606, 2009. [CrossRef] [Google Scholar] [Publisher Link]

[63] Nazila Kamaly et al., "Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation," *Chemical Society Reviews*, vol. 41, no. 7, pp. 2971-3010, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[64] Priya Bawa et al., "Stimuli-Responsive Polymers and Their Applications in Drug Delivery," *Biomedical Materials*, vol. 4, 2009. [CrossRef] [Google Scholar] [Publisher Link]

[65] S.R Croy, and G.S Kwon, "Polymeric Micelles for Drug Delivery," *Current Pharmaceutical Design*, vol. 12, no. 36, pp. 4669-4684, 2006. [CrossRef] [Google Scholar] [Publisher Link]

[66] Jianjun Cheng, and Suzie H. Pun, "Polymeric Biomaterials for Cancer Nanotechnology," *Biomaterials Science*, vol. 3, no. 7, pp. 891-893, 2015. [CrossRef] [Google Scholar] [Publisher Link]

[67] Brian E. Grottkau et al., "Polymeric Nanoparticles for A Drug Delivery System," *Current Drug Metabolism*, vol. 14, no. 8, pp. 840-846, 2013. [CrossRef] [Google Scholar] [Publisher Link]

[68] Kore, Girish et al., "Polymeric Micelle as Multifunctional Pharmaceutical Carriers," *Journal of Nanoscience and Nanotechnology*, vol. 14, no. 1, pp. 288-307, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[69] Nobuhiro Nishiyama, Yasuhiro Matsumura, and Kazunori Kataoka, "Development of Polymeric Micelles for Targeting Intractable Cancers," *Cancer Science*, vol. 107, no. 7, pp. 867-874, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[70] Deepti Pandita, Sandeep Kumar, and Viney Lather, "Hybrid Poly (Lactic-Co-Glycolic Acid) Nanoparticles: Design and Delivery Prospectives," *Drug Discovery Today*, vol .20, no. 1, pp. 95-104, 2015. [CrossRef] [Google Scholar] [Publisher Link]

[71] Kamlesh Shroff, and Ajay Vidyasagar, "Polymer Nanoparticles: Newer Strategies towards Targeted Cancer Therapy," *Journal of Physical Chemistry and Biophysics*, vol. 3, no. 4, pp. 1-3, 2013. [CrossRef] [Google Scholar] [Publisher Link]

[72] Karel Ulbrich et al., "Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies," *Chemical Reviews*, vol. 116, no. 9, pp. 5338-5431, 2016. [CrossRef] [Google Scholar] [Publisher Link]

[73] Hongyan Xu et al., "Targeted Polymer-Drug Conjugates: Current Progress and Future Perspective," *Colloids and Surfaces B: Biointerfaces*, vol. 136, pp. 729-734, 2015. [CrossRef] [Google Scholar] [Publisher Link]

[74] Takayuki Yoshida et al., "pH- And Ion-Sensitive Polymers for Drug Delivery," *Expert Opinion on Drug Delivery*, vol. 10, no. 11, pp. 1497-1513, 2013. [CrossRef] [Google Scholar] [Publisher Link]